GL1X · GenesisL1 explorer

MolNFT v1 · #135247 · protein

Minor pilin fctb from S. pyogenes with engineered intramolecular isopeptide bond

5TTD · Maltose-binding periplasmic PROTEIN,PILIN isopeptide…: “Minor pilin fctb from S. pyogenes with engineered intramolecular isopeptide bond”. X-ray diffraction, 1 ligand (GLC), 7 pockets (best druggability 0.79). MolNFT v1 #135247 on…

PDB
5TTD
Type
protein
Length
852 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Maltose-binding periplasmic PROTEIN,PILIN isopeptide linkage domain protein
UniProt
P0AEY0, U2UUZ4
Ligands
GLC
Pockets
7 · best druggability 0.79

Structure

x-ray diffraction · 2 distinct chains · 38% helix, 27% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AMaltose-binding periplasmic PROTEIN,PILIN isopeptide linkage domain proteinprotein49133% helix, 30% strandP0AEY0, U2UUZ4
BMaltose-binding periplasmic PROTEIN,PILIN isopeptide linkage domain proteinprotein36145% helix, 22% strandP0AEY0, U2UUZ4

Ligands and binding sites

  • GLC · alpha-D-glucopyranose · sugar · 6 copies · chains A, B
  • FMT · Formic acid · additive · 4 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

7 pockets found on a 1 Å grid, 4 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
16940.790.8361GLC
23410.740.8532GLC
34410.730.8347empty
46010.640.7558empty
5550.330.7717empty

Interfaces

1 interface between chains.

  • A–B · 969 Ų buried · 10 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 1 isopeptide (isopeptide).

Compared structures

  • 5TTD · Minor pilin FctB from S. pyogenes with engineered intramolecular isopeptide bond · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.